such as from X-rays or CT scans, especially at a very young age, may have an increased risk of leukemia. It's challenging to determine how much extra risk this gives you since it depends on what type of radiation you had, for how long, if it's repeated exposure, and how young ...
Improved Survival Rates Among Acute Myeloid Leukemia (AML) Patients 65 to 74 Years: Population-Based Estimates Over Three Decades,Mya S TheinAhmedin JemalMaria R. BaerWilliam B ErshlerJerome W Yates
参考文献：Slezak, A. J., et al. (2024). Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia. Blood Advances. doi.org/10.1182/bloodadvances.2023012529.
Investigates the relevance of in vitro leukemia cell survival to the overall survival of patients with acute myeloid leukemia (AML) using MTT-assay. Absence of correlation of leukemia cell survival and Bcl-2 expression; Association of growth factor withdrawal with rapid onset of cellular apoptosis.被...
Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options, depending solely on cytarabine + anthracycline (7 + 3) intensive chemotherapy and hypomethylating agents. Allogeneic stem cell transplantation (Allo
In conclusion, lenalidomide treatment does not increase AML progression risk, but instead confers a possible survival benefit in RBC transfusion- dependent patients with del(5q) Low- or Int-1-risk MDS. Leukemia (2013) 27, 1072–1079; doi:10.1038/leu.2012.369 Keywords: Myelodysplastic syndromes; ...
Leukemia | 研究首次发现DDX11突变与细胞遗传学正常的AML复发相关 成果名称:在细胞遗传学正常的成人急性髓性白血病患者中,DEAD/H-box解旋酶11突变与复发风险增加相关 发表期刊:《白血病》[Leukemia,IF(2022):11.4] 通讯作者:黄晓军,阮国瑞 第一作者:周亚兰,赵鸣悦...
Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 1997; 80 (11 Suppl): 2191–2198. Article CAS Google Scholar Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T . Karyotype is an...
Prognosis of acute myeloid leukemia (AML) patients depends on patient-related features, disease manifestations at the time of presentation, and intrinsic disease-related genetic features, such as cytogenetic abnormalities and driver mutations. Prognostic
The effective treatment of acute myeloid leukemia (AML) is very challenging. Due to the immense heterogeneity of this disease, treating it using a “one size fits all” approach is ineffective and only benefits a subset of patients. Instead, there is a s